Mocravimod

Summary

Mocravimod (CHEMBL2137148) is a phase-3 clinical-stage small molecule; indicated across 4 conditions including ulcerative colitis and cutaneous lupus erythematosus.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 4 conditions
• Clinical trials: 2
• Chemistry: 444 Da · C24H26ClNO3S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2137148
Name	Mocravimod
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	11155874
Molecular formula	C24H26ClNO3S
Molecular weight	444
InChIKey	IINUNQPYJGJCJI-UHFFFAOYSA-N

SMILES: C1=CC=C(C=C1)COC2=CC(=CC=C2)SC3=CC(=C(C=C3)CCC(CO)(CO)N)Cl

IUPAC name: 2-amino-2-[2-[2-chloro-4-(3-phenylmethoxyphenyl)sulfanylphenyl]ethyl]propane-1,3-diol

Also known as: KRP-203, Krp203, KRP203, Mocravimod, SID137275890, MOCRAVIMOD

Parent form; salt/anhydrous children: CHEMBL6068394

Patent coverage: 122 distinct patent families (403 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 394 (98%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
ulcerative colitis	2	MONDO:0005101	EFO:0000729
cutaneous lupus erythematosus	2	MONDO:0005282	EFO:0003834
lymphoid neoplasm	1	MONDO:0005157	EFO:0001642
hematopoietic and lymphoid system neoplasm	1	MONDO:0002334	MONDO:0002334

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05429632	PHASE3	RECRUITING	Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
NCT01375179	PHASE2	TERMINATED	Efficacy & Safety in Moderately Active Refractory Ulcerative Colitis Patients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).